✨ Free AI Report
Tyra Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Tyra Biosciences, Inc.
Company Research

Tyra Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Tyra Biosciences, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage FGFR3-focused biotech with differentiated selectivity profile, strong cash position, multiple upcoming catalysts, and bullish analyst consensus targeting high-value oncology and rare disease indications. 9 analysts recommend buying the stock with a Strong Buy rating. The company holds $256.0 million in cash and marketable securities with stated runway through.

What is Tyra Biosciences, Inc.'s industry? Tyra Biosciences, Inc. (tyra.bio) operates in Precision Oncology / Biotechnology. AskCyborg classifies Tyra Biosciences, Inc. under Precision Oncology / Biotechnology in its company registry.

Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The company offers SNÅP, a precision...

8/ 10Strong

Cyborg Score thesis

Clinical-stage FGFR3-focused biotech with differentiated selectivity profile, strong cash position, multiple upcoming catalysts,...

Read the full analyst-debate transcript →
Industry Precision Oncology / Biotechnology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Tyra Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Tyra Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Tyra Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Tyra Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Tyra Biosciences, Inc. Overview

Pro stress-test →

Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Strategic Profile

Pro stress-test →

Tyra has outlined its "dabogratinib 3x3" strategy targeting LG-UTUC, IR NMIBC and achondroplasia, with oral dabogratinib as a potential first-in-class selective FGFR3 inhibitor. CEO Todd Harris narrowed the company's focus to "highest value opportunities" for dabogratinib in three lead areas: low-grade upper tract urothelial carcinoma (UTUC), intermediate-risk non-muscle invasive bladder cancer (NMIBC), and skeletal dysplasias with achondroplasia.

Competitive Landscape

Pro stress-test →

Tyra is a precision oncology company integrating bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors, leveraging genomic datasets to address populations with high unmet medical need. Competitors include other FGFR inhibitor developers (Loxo, BridgeBio) and precision oncology platforms in early-stage development.

Industry Context

Tyra Biosciences, Inc. operates in Precision Oncology / Biotechnology.

Key facts

Founded: 2015 · Headquarters: Carlsbad, US · Employees: 60 · Revenue: $0B · Market cap: $1.63B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Tyra Biosciences, Inc..

  • Dabogratinib's selectivity is designed to reduce toxicities associated with FGFR1 and FGFR2 inhibition, which have complicated the use of pan-FGFR inhibitors.
  • Full-year 2025 R&D rose to $102.9M with net loss of $119.9M.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • March 2026Narrowed dabogratinib focus to "3x3" strategy targeting LG-UTUC, IR NMIBC and achondroplasia
  • March 2026Reported Q4 and FY 2025 results with $256M cash runway through 2027
  • +2 moreTrack every material event for Tyra Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Tyra Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Erdafitinib/FGFR inhibitorsApproved pan-FGFR inhibitor with broader toxicity profile→CNP-based therapies for achondroplasiaEstablished competitor in skeletal dysplasia treatment→FGFR3 selective inhibitor programsCompeting FGFR3-selective program with different tolerability profile→

Compare Tyra Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Tyra Biosciences, Inc. operates in Precision Oncology / Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Oncology / Biotechnology research →
NEW · MCP server

Ask your AI assistant about Tyra Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Tyra Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Tyra Biosciences, Inc. do this quarter?”
“Is Tyra Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Tyra Biosciences, Inc. do?+
Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The company offers SNÅP, a precision...
What is Tyra Biosciences, Inc.'s Cyborg Score?+
Tyra Biosciences, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Tyra Biosciences, Inc.'s main competitors?+
Named competitors include Erdafitinib/FGFR inhibitors, CNP-based therapies for achondroplasia, FGFR3 selective inhibitor programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Tyra Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Tyra Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Tyra Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Revolution Medicines, Inc.7Erasca, Inc.6Acrivon Therapeutics, Inc.5Personalis, Inc.4PMV Pharmaceuticals, Inc.